Glioblastoma Multiforme Market Size, Share, Growth, Global Trends, Industry Analysis and Forecast to 2027

Price: 3200/- USD | Published Date: September 8, 2020 |

The global glioblastoma multifrome market has been projected to grow at the CAGR of 10.9% market during 2018-2027 and expected to reach up to $ 1,008.1 million in terms of revenue by 2025. Glioblastoma multiforme (GBM) is the most common and most malignant of the glial tumors. It is the most common brain tumor in adults and also the most antagonistic form of brain tumor. U.S. National Cancer Institute states that Glioblastoma multiforme accounts for almost 15.4% of all primary brain tumors and about 60%-75% of all astrocytoma. Moreover, as per the World Health Organization (WHO), the incidence rate of GBM is 2 to 3 per 100,000 people in the U.S. and Europe.

Market Insights:

Glioblastoma multiforme (GBM) is the most common and most malignant of the glial tumors. It is the most common brain tumor in adults and also the most antagonistic form of brain tumor. U.S. National Cancer Institute states that Glioblastoma multiforme accounts for almost 15.4% of all primary brain tumors and about 60%-75% of all astrocytoma. Moreover, as per the World Health Organization (WHO), the incidence rate of GBM is 2 to 3 per 100,000 people in the U.S. and Europe. By type of drugs, the glioblastoma multiforme market was dominated by temozolomide due to delayed progression of temozlomide without impacting the quality of life and lower side effects as compared to other molecules. Moreover, the combination of radiotherapy and temozolomide chemotherapy is suggested by many medical practitioners as a standard treatment for glioblastoma multiforme.

In terms of geography, North America and Europe dominated the global glioblastoma multiforme market. The critical success factors supporting the growth of glioblastoma multiforme market in these regions include growing government initiatives and private organizations to increase public awareness related to diagnosis and treatment of glioblastoma multiforme and advanced healthcare infrastructure to boost the pipeline research in this market. Asia-Pacific is expected to grow at a significant rate were with Japan, China, and India leading the glioblastoma multiforme market respectively.

Market Segment Insights:

The global glioblastoma market for the purpose of this study is studied for drugs. The major drugs for the treatment of glioblastoma multiforme are temozolomide, bevacizumab and carmustine. The glioblastoma multiforme market was dominated by temozolomide due to delayed progression of temozlomide without impacting the quality of life and lower side effects as compared to other molecules. Moreover, the combination of radiotherapy and temozolomide chemotherapy is suggested by many medical practitioners as a standard treatment for glioblastoma multiforme. Strong pipeline would further drive the glioblastoma multiforme market in the future.

Global Glioblastoma multiforme Market Segmentation:

By Drug, 2018–2027 ($ Million)

  • Temozolomide
  • Bevacizumab
  • Carmustine
  • Pipeline Analysis (Projected sales of Phase III Drugs estimated till 2027 ($ Million)

By Geography, 2018-2027 ($ Million)

  • North America
  • Europe
  • Asia Pacific
  • Latin America (LATAM)
  • Middle East and Africa (MEA)

Regional Insights:

For the purpose of this study, the global glioblastoma multiforme market is regionally categorized into North America, Europe, Asia Pacific, Latin America, and Middle East and Africa markets. These regional markets are further sub-segmented into top country level markets that majorly determine the regional industry trends. Among the considered regional markets, North America currently dominates the global glioblastoma multiforme market, with the U.S. being the largest county-level market growing government initiatives and private organizations to increase public awareness related to diagnosis and treatment of glioblastoma multiforme and advanced healthcare infrastructure to boost the pipeline research in this market. Asia-Pacific is expected to grow at a significant rate where with Japan, China and India leading the glioblastoma multiforme market respectively.

Market Competition Assessment:

The major players currently operating in the global glioblastoma multiforme market include AbbVie, Inc., Activartis GmbH, Agenus Inc., Arog Pharmaceuticals, Inc., Bristol-Myers Squibb Company, Cavion LLC, Celldex Therapeutics, Inc., CTI BioPharma Corporation, Cortice Biosciences Inc., Eisai Co., Ltd., F. Hoffmann-La Roche Ltd., Exelixis Inc., and Peregrine Pharmaceuticals, Inc.

List of Key Companies:

  • AbbVie, Inc.
  • Activartis GmbH
  • Agenus Inc.
  • Arog Pharmaceuticals, Inc.
  • Bristol-Myers Squibb Company
  • Cavion LLC
  • Celldex Therapeutics, Inc.
  • CTI BioPharma Corporation (Formerly Cell Therapeutics Inc.)
  • Cortice Biosciences Inc.
  • Eisai Co., Ltd.
  • Hoffmann-La Roche Ltd.
  • Exelixis Inc.
  • Peregrine Pharmaceuticals, Inc.
  • Others

Request a free report sample @ https://www.researchcorridor.com/request-sample/?id=144357


(Reports will be updated due to COVID-19 impacts on the market)

Request Report Sample
Inquiry Before Buying

Table of Content:


1. Preface


1.1. Report Scope and Description
1.2. Research Methodology

2. Executive Summary


2.1. Global Glioblastoma Multiforme Market Snapshot
2.2. Global Glioblastoma Multiforme Market, by Drugs, 2016 ($ Million)
2.3. Global Glioblastoma Multiforme Market, by Geography, 2016 (Value %)

3. Global Glioblastoma Multiforme Market Analysis


3.1. Global Glioblastoma Multiforme Market Overview
3.2. Market Dynamics
3.2.1. Market Drivers
3.2.2. Challenges
3.2.3. Opportunities
3.3. Attractive Investment Proposition, 2016
3.4. Competitive Landscape Assessment, By Key Market Players

4. Global Glioblastoma Multiforme Market, By Application, 2015 – 2025 ($ Million)


4.1. Overview
4.2. Bevacizumab
4.3. Temozolomide
4.4. Carmustine
4.5. Pipeline Analysis
4.5.1. Projected sales of Phase III Drugs estimated till 2022 (US$ Mn)
4.5.1.1. TRC-105
4.5.1.2. VB-111
4.5.1.3. TOCA 511
4.5.1.4. DCVax-Brain
4.5.1.5. Rindopepimut (CDX-110)
4.5.1.6. ICT-107
4.5.1.7. Others
4.5.2. Tabular Representation of Phase II and I Drugs

5. Global Glioblastoma Multiforme Market, By Geography, 2015 – 2025 ($ Million)


5.1. Overview
5.2. North America
5.2.1. U.S.
5.2.2. Canada
5.3. Europe
5.3.1. U.K.
5.3.2. Germany
5.3.3. Rest of Europe
5.4. Asia Pacific
5.4.1. China
5.4.2. Japan
5.4.3. Rest of APAC
5.5. Latin America
5.6. Middle East and Africa

6. Company Profiles


6.1. AbbVie, Inc.
6.1.1. Business Description
6.1.2. Financial Health and Budget Allocation
6.1.3. Product Positions/Portfolio
6.1.4. News Coverage
6.2. Activartis GmbH
6.3. Agenus Inc.
6.4. Arog Pharmaceuticals, Inc.
6.5. Bristol-Myers Squibb Company
6.6. Cavion LLC
6.7. Celldex Therapeutics, Inc.
6.8. CTI BioPharma Corporation (Formerly Cell Therapeutics Inc.)
6.9. Cortice Biosciences Inc.
6.10. Eisai Co., Ltd.
6.11. F. Hoffmann-La Roche Ltd.
6.12. Exelixis Inc.
6.13. Peregrine Pharmaceuticals, Inc.
6.14. Others
Fill the given form to inquiry before buying for Glioblastoma Multiforme Market Report

Your Designtaion (required):

Select License Type
$3200/- Single User License
$4800/- Multi User License
$6400/- Corporate License

Why To Choose Us:
  • Markets in over 150 countries analyzed granularly
  • 35% of our total client base has an annual subscription membership
  • 24x7 availability we are always there when you need us
  • 100,000+ data points in our comprehensive database
  • Our expert team will assist you with all research need and customization
  • Our expert research analysts will resolve your every query before and after purchasing the report
  • We focus on the accuracy and quality of the report
  • Our analyst will provide deep insights into the report
For Any Assitance
Call Us: +919893685690
Contact Person: Mr. Vijendra Singh
Contact Email: sales@researchcorridor.com